Skip to main
PTGX

Protagonist Therapeutics (PTGX) Stock Forecast & Price Target

Protagonist Therapeutics (PTGX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 31%
Buy 62%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Protagonist Therapeutics Inc is positioned favorably due to its promising pipeline, particularly with icotrokinra, which shows significant dose-dependent improvements in clinical responses and remission rates over time, indicating its potential as a key player in the biopharmaceutical market. The company's strong business development track record and expected momentum from key catalysts leading into 2025 further enhance its growth prospects. Additionally, encouraging data on icotrokinra's efficacy and safety, particularly in challenging treatment areas, bolsters the outlook for successful market entry and widespread adoption once regulatory approvals are obtained.

Bears say

Protagonist Therapeutics Inc faces significant risks that contribute to a negative outlook on its stock, including potential safety concerns arising from ongoing clinical trials and the possibility of its strategic partners opting not to advance the development of key drug candidates like Icotrokinra (formerly JNJ-2113). Furthermore, the company is exposed to increased regulatory, competitive, and pricing risks, particularly in an evolving market that may affect the pricing and adoption of its therapeutic products. Additionally, there is concern over future cash requirements, which might necessitate dilution, further complicating the company’s financial position.

Protagonist Therapeutics (PTGX) has been analyzed by 13 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 62% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Protagonist Therapeutics (PTGX) Forecast

Analysts have given Protagonist Therapeutics (PTGX) a Buy based on their latest research and market trends.

According to 13 analysts, Protagonist Therapeutics (PTGX) has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $81.15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $81.15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Protagonist Therapeutics (PTGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.